See how other scientists are using Thermo Fisher Scientific gene expression solutions
Read some testimonials from key opinion leaders in gene expression analysis about how our cross-technology solutions assisted in their research.
Lecturer in Functional Genomics, Wolfson Centre for Age-Related Diseases, King’s College London, UK
Research area: Neurodegenerative diseases
Product focus: Applied Biosystems microarrays for transcriptome profiling
“I think we are standing on the precipice of genomic drug discovery. This is really one of the very first initiatives where we’ve tried to research what a drug can do in terms of gene expression with what’s happening with the disease."
Institute of Biomedical Technologies, National Research Council of Bari
Research area: Neurological diseases
Product focus: TaqMan Advanced miRNA Assays
“There is an urgent need to identify possible molecular signatures that allow us to decipher the pathogenetic mechanism in multifactorial neurodegenerative diseases, which could potentially provide critical information for the selection of those circulating biomarkers (e.g., miRNAs) best suited for therapeutic efforts and/or monitoring the progression of these diseases."
Professor, Renaissance School of Medicine, Stony Brook University
Research area: Cancer therapeutics
Product focus: TaqMan miRNA Assays
“As miRNAs are multitargeted entities by interacting with a number of mRNA transcripts, they will provide multitargeted inhibitors, which is a dream for anticancer drug development.”
Dr. Ju is a Professor in the Department of Pathology and Co-Director of the Translational Research Laboratory at Renaissance School of Medicine, Stony Brook University.
His research focuses on elucidating the mechanism of translational control mediated by noncoding RNAs in cancer and translating the new discovery to clinical cancer diagnosis and therapy. His group was the first to discover that p53 regulates the expression of certain miRNAs, opening a new frontier in cancer research. His group is developing novel approaches to study posttranscriptional control mediated by miRNAs and RNA-binding proteins. They are also interested in translational research and the investigation of miRNAs as biomarkers in cancer diagnosis and prognosis.
We interviewed Dr. Ju regarding his research. Download the full interview or watch his webinar to learn more about miRNA-based biomarkers and therapeutics for cancer.
Division of Cancer Sciences, The University of Manchester
Research area: Tumor biology
Product focus: Clariom S Assay
“Because of the samples that we deal with, there are generally certain technologies that work better for discovery, and others that work better for development and analytical validation of the changes in the transcriptome that we’re interested in. ”
Dr. Darren Roberts, Research Associate in the Division of Cancer Sciences at The University of Manchester, is interested in how and why cells die. Dr. Roberts joined The University of Manchester in 2004 to investigate the role of hypoxia on chemotherapy resistance and has since worked on the identification of biomarkers for a range of cancers and on the development of gene signatures to detect hypoxia in prostate and bladder cancer in order to personalize treatment for patients undergoing radiotherapy.
We interviewed Dr. Roberts regarding cancer transcriptomics and radiobiology. Download the full interview to learn more about how changes in the transcriptome reflect tumor biology and predict response to radiotherapy.
“One of the research projects we were working on was defining the transcriptomic landscape in type 2 diabetes. Type 2 diabetes is one of the cornerstones of metabolic syndrome, which comprises a cluster of metabolic abnormalities [that includes] cancer and cardiovascular disease and has accompanied the secular rise in obesity we’re seeing across the world. ”
Dr. Iain Gallagher, Lecturer in the faculty of Health Sciences and Sport at the University of Stirling, is interested in the effects of metabolic disease on muscle functions. In a recent research study, he set out to define the transcriptomic landscape in type 2 diabetes.
We interviewed Dr. Gallagher about his research. Download the full interview to learn more about high-throughput transcriptomics in human metabolic disease research.
“In 40% of cases, the cause [of stroke] is never determined. We’ve developed the final version of a blood test for the cause of stroke, the ISCDx test”
Jeff June is CEO, founder, investor, and board member of Ischemia Care, a molecular diagnostics company that commercializes blood tests for cause of stroke.
Ischemia Care ran the largest stroke biomarker trial that’s ever been conducted and recruited over 1,600 patients that have helped identify distinct signatures.
We interviewed Mr. June regarding Ischemia Care. Download the full interview to learn more about stroke research and their blood test for cause of stroke, ISCDx.
Associate Research Professor, Department of Pathology and Laboratory Medicine, Indiana University School of Medicine
Research area: Breast cancer
Product focus: Clariom D Pico Assay and Transcriptome Analysis Console software
“Overexpression of this gene [ESRP1] … plays a role in ER-positive breast cancer resistance to endocrine therapies.”
Dr. Polar is an Associate Research Professor of Pathology and Laboratory Medicine at the Indiana University School of Medicine, interested in the identification of novel therapeutic targets in cancers that are resistant to standard-of-care therapy.
She focuses on biomarkers that alter the prognosis in ER-positive breast cancers and recently demonstrated that overexpression of splicing factor ESRP1 alters the metabolic pathway genes and plays a role in ER-positive breast cancer resistance to endocrine therapies.
We interviewed Dr. Polar regarding her research. Download the full interview to learn more about identifying ways to prevent the development of cancer drug resistance and recurrence, particularly in breast cancer.
“Over the past decade, we’ve begun to realize that aging is not a given, or an immutable thing that you can’t influence.”
Dr Harries is a Professor of Molecular Genetics at the University of Exeter Medical School, with an interest in gene regulation and alternative mRNA processing in human aging.
As head of the RNA-Mediated Mechanisms of Disease group, she leads the investigation into how and why we age, and the reason age is a major risk factor in diseases like type 2 diabetes.
We interviewed Dr. Harries regarding her aging research. Download the full interview to learn more about aging research and the information the group uncovers to develop a new generation of antidegenerative drugs.
Antonia Sepulveda, MD, PhD
Chair of the Department of Pathology, George Washington University
Research area: Gastrointestinal cancers
Product focus: OncoScan CNV Assay, OncoScan FFPE Services, and GeneChip Human Transcriptome Array 2.0
“One of my research goals is to discover tissue biomarkers that can be tested in patients’ tissues that we use for routine diagnosis: namely, FFPE tissues.”
Dr Sepulveda, a physician-scientist and Chair of Pathology at George Washington University in Washington, DC, is an expert in gastrointestinal pathology and molecular diagnostic pathology of cancer.
Her research is focused on an innovative integromics cancer research program that is exploring computationally generated networks that integrate the molecular mechanisms and biomarkers of gastric, esophageal, and pancreatic cancers and pre-cancer lesions.
We interviewed Dr. Sepulveda regarding her research projects and clinical practice. Download the full interview to learn more about biomarkers in cancer research and precision medicine.
Ryo Fujii, PhD
Associate Director, Axcelead Drug Discovery Partners, Inc.
Research area: Drug Discovery
We spoke with Dr. Ryo Fujii, Associate Director at the Japanese pharmaceutical company Axcelead Drug Discovery Partners, Inc., where he leads genomics, transcriptomics, and bioinformatics in the company’s Integrated Biology Group. He uses gene expression analysis techniques with tissue cultures, animal models, and clinical samples as indices for investigating the mechanism of drug action and for confirming pharmacokinetics.
For Research Use Only. Not for use in diagnostic procedures.